ISOPTIN

This brand name is authorized in Austria, Australia, Canada, Cyprus, Germany, Estonia, Finland, Hong Kong, Croatia, Ireland, Italy, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, South Africa

Active ingredients

The drug ISOPTIN contains one active pharmaceutical ingredient (API):

1 Verapamil UNII V3888OEY5R - VERAPAMIL HYDROCHLORIDE

Verapamil inhibits the transmembrane influx of calcium ions into the heart and vascular smooth muscle cell. The myocardial oxygen demand is lowered directly as a result of the effect on the energy consuming metabolic processes of the myocardial cell and indirectly due to a reduction of the afterload. Due to its effect on coronary vascular smooth muscle, verapamil enhances myocardial blood flow, even in post‐stenotic areas, and relieves coronary spasms. These properties contribute to the anti‐ischaemic and antianginal efficacy of verapamil in all types of coronary artery disease. Read about Verapamil

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ISOPTIN Solution for injection / infusion	Health Products Regulatory Authority (IE)	MPI, EU: SmPC
ISOPTIN Film‐coated tablet	Health Products Regulatory Authority (IE)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C08DA01	Verapamil	C Cardiovascular system → C08 Calcium channel blockers → C08D Selective calcium channel blockers with direct cardiac effects → C08DA Phenylalkylamine derivatives
Discover more medicines within C08DA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 1241H, 1250T, 2208F
Country: CA	Health Products and Food Branch	Identifier(s): 00742554, 01907123, 01934317
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 00530896, 01284330, 01976772, 02459323, 02709406, 02709458, 02709464, 02791342, 03573825, 03573831
Country: EE	Ravimiamet	Identifier(s): 1017267, 1017278, 1073157, 1073180
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 508622, 559021
Country: HK	Department of Health Drug Office	Identifier(s): 01261, 26481
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-043595484, HR-H-343032655, HR-H-487117669, HR-H-998142642
Country: IE	Health Products Regulatory Authority	Identifier(s): 29424, 29521, 29548, 38933, 39470
Country: IT	Agenzia del Farmaco	Identifier(s): 020609044, 020609069, 020609083
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1002853, 1002855, 1090534
Country: MT	Medicines Authority	Identifier(s): AA1187/01601, AA1187/01602, AA565/78701
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 26832, 34800, 35408
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 1665, 1666, 1667, 1669, 1670
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100010337, 100030363, 100031434, 100032391, 100426411, 100446632, 100449056, 100458000, 100463200
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68848001
Country: SG	Health Sciences Authority	Identifier(s): 00344P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699548030420, 8699548031953, 8699548090806, 8699548090820, 8699548750793, 8699548755255, 8699548755262
Country: ZA	Health Products Regulatory Authority	Identifier(s): D/7.1.4/118, R/7.1.4/195, V/7.1/280